Weight loss: FDA accepts EnteroMedics' submission of VBLOC neurostim implant

July 26, 2013 by Arezu Sarvestani

FDA regulators accept for review EnteroMedics' premarket approval application for the Maestro VBLOC vagal blocking therapy as a treatment for obesity.

Weight loss: FDA accepts EnteroMedics' submission of VBLOC neurostim implant

Minnesota medical devices maker EnteroMedics (NSDQ:ETRM) touted today that the FDA had accepted for review the company's premarket approval submission of the Maestro Rechargeable System's VBLOC implant, a neurostimulation device for treating obesity.

The news sent ETRM shares skyrocketing, trading up by nearly a quarter by the early afternoon today.

The VBLOC system stimulates the vagus nerve, located between the stomach and the esophagus, in order to alter a patient's eating habits by modifying their physiological cravings.

Sign up to get our free newsletters delivered right to your inbox.

Maestro delivers VBLOC therapy through 2 laparoscopically implanted leads that intermittently block the vagus nerves using high-frequency, low-energy electrical impulses. The therapy is powered by an internal battery, which is recharged via an external mobile charger and transmit coil that the patient uses for a short time each week.

Check out MassDevice's Q&A with EnteroMedics CEO Mark Knudson and CFO Greg Lea

Comments